Cassava Sciences (SAVA) said Tuesday that topline results from its phase 3 REFOCUS-ALZ study of simufilam showed no treatment benefit for patients with mild-to-moderate Alzheimer's disease.
The biotech company said the results did not meet the co-primary, secondary, and exploratory biomarker endpoints.
The co-primary endpoints were the change in cognition and function from baseline to the end of the double-blind treatment period at week 76 compared to placebo.
Shares of Cassava Sciences were down 18% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.